摩根士丹利发表研究报告指,上海医药(02607.HK) 首季收入为753亿元人民币,按年增长6.4%,纯利为14.18亿元人民币,按年增长6.4%,两者均符合该行预期。大摩提到,上海医药目前正与美国及欧盟跨国的企业,就其研发管线的潜在业务发展机会进行磋商。该行予上海医药(601607.SH) A股“与大市同步”评级,目标价18.8元人民币。(sl/j)(港股报价延迟最少十五分钟。沽空资料截至 ...
Source Link摩根士丹利发表研究报告指,上海医药(02607.HK) 首季收入为753亿元人民币,按年增长6.4%,纯利为14.18亿元人民币,按年增长6.4%,两者均符合该行预期。大摩提到,上海医药目前正与美国及欧盟跨国的企业,就其研发管线的潜在业务发展机会进行磋商。该行予上海医药(601607.SH) A股“与大市同步”评级,目标价18.8元人民币。(sl/j)(港股报价延迟最少十五分钟。沽空资料截至 ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.